Ashwin Gollerkeri

4.7k total citations · 1 hit paper
66 papers, 2.2k citations indexed

About

Ashwin Gollerkeri is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ashwin Gollerkeri has authored 66 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 24 papers in Molecular Biology. Recurrent topics in Ashwin Gollerkeri's work include Colorectal Cancer Treatments and Studies (29 papers), Lung Cancer Treatments and Mutations (20 papers) and Cancer Treatment and Pharmacology (16 papers). Ashwin Gollerkeri is often cited by papers focused on Colorectal Cancer Treatments and Studies (29 papers), Lung Cancer Treatments and Mutations (20 papers) and Cancer Treatment and Pharmacology (16 papers). Ashwin Gollerkeri collaborates with scholars based in United States, Italy and Spain. Ashwin Gollerkeri's co-authors include Andreas Hochhaus, François Guilhot, Steven Coutré, Oliver G. Ottmann, Richard A. Larson, Jane F. Apperley, Prasheen Agarwal, Josep Tabernero, Scott Kopetz and Fortunato Ciardiello and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Ashwin Gollerkeri

65 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

2021 331 citations Josep Tabernero, Axel Grothey et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ashwin Gollerkeri United States	19	1.1k	913	710	687	544	66	2.2k
Narayana I. Narasimhan United States	19	754 0.7×	750 0.8×	604 0.9×	795 1.2×	233 0.4×	41	2.0k
Claude Nicaise United States	20	762 0.7×	1.4k 1.5×	1.1k 1.5×	537 0.8×	739 1.4×	47	2.5k
Raja Luthra United States	24	526 0.5×	607 0.7×	439 0.6×	456 0.7×	296 0.5×	54	1.7k
Nicole Mentens Belgium	22	449 0.4×	765 0.8×	360 0.5×	766 1.1×	362 0.7×	33	2.4k
Preetesh Jain United States	32	1.0k 1.0×	1.4k 1.6×	2.2k 3.1×	668 1.0×	409 0.8×	181	3.7k
Joke W. Baars Netherlands	23	935 0.9×	641 0.7×	507 0.7×	348 0.5×	118 0.2×	52	2.4k
Piers Blombery Australia	26	675 0.6×	749 0.8×	890 1.3×	826 1.2×	78 0.1×	122	2.4k
H. Kantarjian United States	29	637 0.6×	2.4k 2.7×	2.1k 3.0×	995 1.4×	776 1.4×	120	3.9k
Andrzej Hellmann Poland	23	589 0.6×	1.5k 1.6×	1.8k 2.5×	548 0.8×	320 0.6×	58	3.1k
Aude Charbonnier France	24	911 0.9×	2.7k 3.0×	2.0k 2.8×	405 0.6×	1.2k 2.1×	68	3.7k

Countries citing papers authored by Ashwin Gollerkeri

Since Specialization

Citations

This map shows the geographic impact of Ashwin Gollerkeri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashwin Gollerkeri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashwin Gollerkeri more than expected).

Fields of papers citing papers by Ashwin Gollerkeri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashwin Gollerkeri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashwin Gollerkeri. The network helps show where Ashwin Gollerkeri may publish in the future.

Co-authorship network of co-authors of Ashwin Gollerkeri

This figure shows the co-authorship network connecting the top 25 collaborators of Ashwin Gollerkeri. A scholar is included among the top collaborators of Ashwin Gollerkeri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashwin Gollerkeri. Ashwin Gollerkeri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Agarwal, Sagar, Alice McDonald, Dapeng Chen, et al.. (2025). Pharmacokinetics and Pharmacodynamics of KT‐474, a Novel Selective Interleukin‐1 Receptor–Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults. Clinical and Translational Science. 18(3). e70181–e70181. 4 indexed citations

Naqash, Abdul Rafeh, Reva Schneider, Aditi Shastri, et al.. (2024). Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology. 42(16_suppl). 3084–3084. 6 indexed citations

Lue, Jennifer Kimberly, Don A. Stevens, Emmeline Ayers, et al.. (2023). PHASE 1 TRIAL OF KT‐413, A DEGRADER OF IRAK4 AND IMID SUBSTRATES, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMAS. Hematological Oncology. 41(S2). 808–809.

Smith, Stephen D., Adam J. Olszewski, Alexander Starodub, et al.. (2023). Phase 1 trial of KT‐333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors. Hematological Oncology. 41(S2). 567–568. 1 indexed citations

Tabernero, Josep, Axel Grothey, Eric Van Cutsem, et al.. (2021). Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology. 39(4). 273–284. 331 indexed citations breakdown →

Desai, Jayesh, Scott Kopetz, Axel Grothey, et al.. (2021). Global BRAF testing practices in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 39(15_suppl). e15523–e15523. 1 indexed citations

Tabernero, Josep, Axel Grothey, Rona Yaeger, et al.. (2021). Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open. 6(6). 100328–100328. 15 indexed citations

Yeh, Kun‐Huei, Jayesh Desai, Timothy Price, et al.. (2020). 85MO Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study). Annals of Oncology. 31. S1276–S1276. 1 indexed citations

Kopetz, Scott, Axel Grothey, Eric Van Cutsem, et al.. (2020). Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. Journal of Clinical Oncology. 38(15_suppl). 4001–4001. 32 indexed citations

10.

Kopetz, Scott, Axel Grothey, Eric Van Cutsem, et al.. (2020). Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. Journal of Clinical Oncology. 38(15_suppl). 4039–4039. 19 indexed citations

11.

Grothey, Axel, Scott Kopetz, Rona Yaeger, et al.. (2020). LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC. Annals of Oncology. 31. S243–S243. 1 indexed citations

12.

Ascierto, Paolo A., Reinhard Dummer, Helen Gogas, et al.. (2020). Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma. European Journal of Cancer. 126. 33–44. 122 indexed citations

13.

Kopetz, Scott, Axel Grothey, Eric Van Cutsem, et al.. (2019). BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer. Annals of Oncology. 30. iv154–iv154. 14 indexed citations

14.

Huijberts, Sanne C.F.A., Jan H.M. Schellens, Élena Elez, et al.. (2017). BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC). Annals of Oncology. 28. v175–v175. 3 indexed citations

15.

Campo, Josep M. del, Michael J. Birrer, Craig B. Davis, et al.. (2016). A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecologic Oncology. 142(1). 62–69. 82 indexed citations

16.

Coutré, Steven, Giovanni Martinelli, Hervé Dombret, et al.. (2006). Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 ‘START-L’ study. Journal of Clinical Oncology. 24(18_suppl). 6528–6528. 22 indexed citations

17.

Schmitz, John C., Jun Liu, Xiukun Lin, et al.. (2001). Translational Regulation as a Novel Mechanism for the Development of Cellular Drug Resistance. Cancer and Metastasis Reviews. 20(1-2). 33–41. 18 indexed citations

18.

Rose, Michal G., et al.. (2000). The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function. Bone Marrow Transplantation. 26(2). 133–139. 8 indexed citations

19.

Safran, Howard, King T, Hak Choy, et al.. (1996). p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Cancer. 78(6). 1203–1210. 62 indexed citations

20.

Ramratnam, Bharat, Ashwin Gollerkeri, Fred J. Schiffman, Peter Rintels, & Timothy Flanigan. (1995). Management of persistent B19 parvovirus infection in AIDS. British Journal of Haematology. 91(1). 90–92. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact